" class="no-js "lang="en-US"> Daniel O'Connell - Medtech Alert
Thursday, March 30, 2023
Daniel O'Connell

Daniel O’Connell

About Daniel O’Connell

Investor focused on the healthcare space experienced at evaluating novel opportunities across a spectrum of indications and stages of development. Strong analytical skills with special focus on distilling the most salient information into actionable items. Especially skilled at evaluating preclinical data, clinical data, drug development plans, and regulatory strategies, and translating highly technical information into accessible messages across a variety of audiences including clinicians, scientists, generalist investors, and the lay person. Strong passion for novel mechanisms that treat areas of unmet medical need.

Related Story

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

August 25 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]